Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.
Did you mean: ➙ act deep b cell?

NLS Pharmaceutics and Kadimastem announce a $500,000 initial closing of a $1 million fundraising, with shares priced at $3.10, a 48% premium over the January 6, 2025 market price

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. "Kadimastem", a clinical-stage cell...

Axio BioPharma Partners with eMBR Genomics to Manufacture and Distribute Proprietary MKLP1 Pro™ Antibodies

In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic...

Strategic Expansion Expands Fusion Orthopedics' Foot & Ankle Reach

Fusion Orthopedics USA, LLC announced that it has expanded its robust product portfolio with the addition of the Metalogix External Fixation Systems. A seamless transition of Metalogix’s operations, distribution, and hospital accounts to Fusion is...

Nona Biosciences Updates on ADC Collaboration with BeiGene and DualityBio

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" announced that BeiGene. Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an...

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a...

ADC Therapeutics shares promising initial LOTIS-7 trial data on ZYNLONTA® combined with a bispecific antibody for relapsed/refractory DLBCL.

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

Neurizon Therapeutics Limited a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal...

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

Aadi Bioscience, Inc. announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand...

Great Bay Bio launches its Intelligent Drug Development Ecosystem

On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB...

Aileron Therapeutics will present Phase 1b trial data on low-dose LTI-03 for IPF at the 22nd International Colloquium on Lung and Airway Fibrosis

Aileron Therapeutics, Inc. a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced the presentation of two abstracts...

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, today unveils the new GloMax® Galaxy Bioluminescence. The GloMax® Galaxy Bioluminescence Imager provides researchers...

LenioBio partners with ReciBioPharm to scale up ALiCE® technology and accelerate vaccine production

LenioBio, the leader in rapid cell-free protein expression technologies, is pleased to announce a collaboration with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale up protein manufacturing capabilities...

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

The ISCT Institute of Training & Development, a division of the International Society for Cell and Gene Therapy (ISCT), has become the first cell and gene therapy (CGT) organization to receive globally recognized accreditation from the ANSI...

Swiss startup Enzian Pharmaceutics is developing a new tablet aimed at enhancing effectiveness and reducing side effects in cancer therapies

The capsules and tablets commonly used today consist of loose or lightly compressed particles of the drug and excipients. After ingestion, they disintegrate almost immediately in the stomach. The small drug particles then flow from the stomach and...

Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits

Cygnus Technologies both part of Maravai LifeSciences (NASDAQ: MRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an...

ProJenX announces the formation of its Clinical Advisory Board

ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, announced the...

Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics

Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, announced major advancements in customer growth, validation through a Quest Diagnostics study, regulatory approvals and expansion of its Board of...

Results 101 - 120 of 139